IL268648B - Therapeutic dendrimers - Google Patents

Therapeutic dendrimers

Info

Publication number
IL268648B
IL268648B IL268648A IL26864819A IL268648B IL 268648 B IL268648 B IL 268648B IL 268648 A IL268648 A IL 268648A IL 26864819 A IL26864819 A IL 26864819A IL 268648 B IL268648 B IL 268648B
Authority
IL
Israel
Prior art keywords
dendrimers
therapeutic
therapeutic dendrimers
Prior art date
Application number
IL268648A
Other languages
English (en)
Hebrew (he)
Other versions
IL268648A (en
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL268648A publication Critical patent/IL268648A/en
Publication of IL268648B publication Critical patent/IL268648B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641Branched, dendritic or hypercomb peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40Polyamides containing oxygen in the form of ether groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL268648A 2017-02-22 2019-08-12 Therapeutic dendrimers IL268648B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US201762591823P 2017-11-29 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (2)

Publication Number Publication Date
IL268648A IL268648A (en) 2019-10-31
IL268648B true IL268648B (en) 2022-04-01

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268648A IL268648B (en) 2017-02-22 2019-08-12 Therapeutic dendrimers

Country Status (23)

Country Link
US (4) US10314920B2 (enExample)
EP (1) EP3585441A1 (enExample)
JP (1) JP7074761B2 (enExample)
KR (2) KR102544033B1 (enExample)
CN (2) CN117582521A (enExample)
AU (1) AU2018223149B2 (enExample)
BR (1) BR112019016409A2 (enExample)
CA (1) CA3053069A1 (enExample)
CL (1) CL2019002240A1 (enExample)
CO (1) CO2019009722A2 (enExample)
CR (1) CR20190361A (enExample)
DO (1) DOP2019000204A (enExample)
EC (1) ECSP19056271A (enExample)
IL (1) IL268648B (enExample)
JO (1) JOP20190191B1 (enExample)
MX (1) MX2019009442A (enExample)
NI (1) NI201900088A (enExample)
PE (1) PE20191660A1 (enExample)
PH (1) PH12019501896A1 (enExample)
SG (1) SG11201907334QA (enExample)
TW (1) TWI773730B (enExample)
UA (1) UA125655C2 (enExample)
WO (1) WO2018154004A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
WO2020225307A1 (en) 2019-05-07 2020-11-12 Syddansk Universitet Mechanism for dispensing biological material
EP4034169B1 (en) * 2019-09-26 2026-02-11 Starpharma Pty Limited Therapeutic dendrimer
US20210170040A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
BR112023000320A2 (pt) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
BR112023002855A2 (pt) 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
EP4203968A4 (en) * 2020-08-31 2025-07-30 Starpharma Pty Ltd DENDRIMER-DRUG CONJUGATE

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
ES2625109T3 (es) * 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
JP5989294B2 (ja) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドStarpharma Pty Ltd 修飾高分子
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
EP2094672B1 (en) 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
DK2376480T3 (en) 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Bcl-2族群抑制劑之口服醫藥劑型
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
IN2014DN00101A (enExample) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) * 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法

Also Published As

Publication number Publication date
JOP20190191B1 (ar) 2024-04-16
BR112019016409A2 (pt) 2020-04-07
KR20230093346A (ko) 2023-06-27
PE20191660A1 (es) 2019-11-11
CA3053069A1 (en) 2018-08-30
JOP20190191A1 (ar) 2019-08-08
WO2018154004A9 (en) 2018-12-27
US20210060172A1 (en) 2021-03-04
CL2019002240A1 (es) 2019-11-29
CN117582521A (zh) 2024-02-23
TW201841659A (zh) 2018-12-01
US10314920B2 (en) 2019-06-11
ECSP19056271A (es) 2019-08-30
AU2018223149A1 (en) 2019-10-03
AU2018223149B2 (en) 2021-04-01
KR20190112330A (ko) 2019-10-04
US10888624B2 (en) 2021-01-12
TWI773730B (zh) 2022-08-11
IL268648A (en) 2019-10-31
CO2019009722A2 (es) 2019-09-18
JP7074761B2 (ja) 2022-05-24
KR102544033B1 (ko) 2023-06-14
PH12019501896A1 (en) 2019-10-21
US20200069810A1 (en) 2020-03-05
SG11201907334QA (en) 2019-09-27
NI201900088A (es) 2020-03-18
EP3585441A1 (en) 2020-01-01
JP2020508985A (ja) 2020-03-26
US20240115716A1 (en) 2024-04-11
DOP2019000204A (es) 2019-08-30
CN110312531A (zh) 2019-10-08
US20180264127A1 (en) 2018-09-20
MX2019009442A (es) 2019-10-09
UA125655C2 (uk) 2022-05-11
US11717574B2 (en) 2023-08-08
WO2018154004A1 (en) 2018-08-30
CR20190361A (es) 2019-09-24

Similar Documents

Publication Publication Date Title
IL268648B (en) Therapeutic dendrimers
EP3463464A4 (en) ASSOCIATION TREATMENT
IL269371A (en) Treatment methods
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
EP3432973A4 (en) COMPACT MUSCLE STIMULATOR
EP3291824C0 (en) ANTIMICROBIAL THERAPY
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
DK3405158T3 (da) Forbedret stimuleringsindretning
DK3612624T3 (da) Genterapi
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
IL260347A (en) Therapeutic anti-cd9 antibody
DK3408265T3 (da) Terapeutiske forbindelser
DK3723488T3 (da) Terapeutiske bakteriociner
IL262851A (en) Combination prime: boost therapy
DK3645090T3 (da) Inhalator
EP3644444A4 (en) CONNECTOR
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
EP3684343A4 (en) IMPROVED SUPRA ITEMS
EP3681458A4 (en) CRUTCH
EP3664226A4 (en) CONNECTOR
DK3329004T3 (da) Terapeutiske oligonukleotider
EP3605745A4 (en) CONNECTION
EP3518957C0 (en) Therapeutic protein
DK3608284T3 (da) Vinde